Alopecia areata in Korea (1982-1994).
I clinically studied 905 patients with alopecia areata (AA) who visited the Department of Dermatology, College of Medicine, Chung Ang University, from January of 1982 to February of 1994. The purpose of the study was to evaluate the clinical manifestations and compare the effects of treatment with intralesional injection of triamcinolone acetonide suspension and immunotherapy with dinitrochlorobenzene (DNCB) or diphenylcyclopropenone (DPCP). The results were as follows: 1) The incidence of AA among all out-patients (59,970) was 1.5% (905 cases), and the ratio of males to females was 1.3:1 (512:393). 2) The age distribution showed high incidences in the third (41.8%) and fourth decades (20.0%). 3) The family history was contributory in 104 cases (11.5%). 4) The relapse rate was 17.5% (158 cases). 5) Almost half of the patients had a solitary lesion (408 cases, 46.7%). 6) The most common site of predilection was the occipital region of the scalp in both male and female patients. 7) Associated diseases were seborrheic dermatitis, atopic dermatitis, hepatitis, hypertension, open heart surgery, thyroid disease, pulmonary disease, and vitiligo in order of frequency. 8) The effect of treatment on the patients who had bald patches less than 50 cm2 was not significantly statistically different between intralesional injection of triamcinolone acetonide and immunotherapy with DNCB or DPCP. 9) In cases with bald areas more than 50 cm2, including alopecia totalis and universalis, DNCB or DPCP immunotherapy showed better therapeutic effects than did intralesional injection of triamcinolone acetonide.
Ro
B I
BI
Department of Dermatology, Yongsan Hospital, College of Medicine, Chung Ang University, Seoul, Korea.
D000293:Adolescent; D000328:Adult; D000506:Alopecia Areata / Q000188:drug therapy / Q000628:therapy*; D002648:Child; D003521:Cyclopropanes / Q000627:therapeutic use; D004137:Dinitrochlorobenzene / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy; D015552:Injections, Intralesional; D007723:Korea; D008297:Male; D008875:Middle Aged; D014222:Triamcinolone Acetonide / Q000008:administration & dosage
D003521:Cyclopropanes; D004137:Dinitrochlorobenzene; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide; C029402:diphenylcyclopropenone